Drug Approval | September 02, 2025
FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
Guidelines aim to establish state-regulated veterinary blood banks
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
